Viking Global Investors reduced stake in Zentalis Pharmaceuticals, Inc.

Viking Global Investors reduced stake in Zentalis Pharmaceuticals, Inc.

© Reuters.  Viking Global Investors reduced stake in Zentalis Pharmaceuticals, Inc. © Reuters. Viking Global Investors reduced stake in Zentalis Pharmaceuticals, Inc.

On the 1st of December, Viking Global Investors sold 500 thousand Zentalis Pharmaceuticals, Inc. (ZNTL) shares for $25 million at an average price of $50.50 per share. Shares of Zentalis Pharmaceuticals, Inc. are down -0.93% since the transaction.

Viking Global Investors's holding in Zentalis Pharmaceuticals, Inc. decreased to about 3.9 million shares with the transaction.

Viking Global Investors first bought Zentalis Pharmaceuticals, Inc. stock in the second quarter of 2020. Viking Global Investors also owns aTyr Pharma, Inc. (NASDAQ:LIFE), Thermo Fisher Scientific Inc (NYSE:TMO), Guardant Health Inc (NASDAQ:GH) and Bristol-Myers Squibb Co (NYSE:BMY). Zentalis Pharmaceuticals, Inc. is its number five position by number of shares and market value among biotechnology & life sciences stocks.

Other investors who also reduced their Zentalis Pharmaceuticals, Inc. shares include the T. Rowe Price Equity Income Fund. Contrary to Viking Global Investors, California State Teachers Retirement System added to ZNTL shares, while Polar Capital established new holdings in Zentalis Pharmaceuticals, Inc.

Original Article

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *